Atrial fibrillation in general practice: mechanisms, management, and ablation
Based on a CPD lecture by Dr Wai Kah Choo, cardiac electrophysiologist, Gold Coast Heart Centre.
Atrial fibrillation (AF) is a journey, not a single on/off event. This summary follows Dr Wai Kah Choo’s “sparky” talk for Gold Coast GPs — plain language covering mechanisms, everyday management, ablation, when to refer early, and a few common clinic scenarios. Electrophysiologists joke that their job is simple: speed up a slow heart and slow down a fast one. AF sits squarely in that second half.
Pathophysiology: triggers, substrate and the AV node
AF is chaotic atrial depolarisation. On the ECG you see an irregular baseline rather than organised P waves. Measured atrial rates in the lab are typically 300–600 beats per minute. So “fast AF” is a slightly misleading phrase — the atria are always fast in AF. What patients and pulse checks feel is the ventricular rate: only some of those atrial impulses get through the AV node (often roughly 120–180 when uncontrolled).
The AV node is the gatekeeper. It blocks most of the atrial chaos from reaching the ventricles. When there is an extra pathway (classic example: Wolff–Parkinson–White), that gatekeeper is bypassed — AF can conduct very rapidly and, rarely, degenerate toward ventricular fibrillation. That is one reason AV node physiology matters so much in AF care.
To have AF you need something to start it (a trigger) and something to sustain it (substrate). Dr Choo’s classroom analogy: you need a naughty kid to start the party, and enough classmates for the party to keep going. Early / paroxysmal AF is often trigger-driven. As AF persists over years, the atrium itself changes — more scarring and “parties” everywhere — so management becomes more substrate-driven.
Most modern catheter ablation aims at the dominant trigger sites: the pulmonary veins (usually four veins draining lungs into the left atrium). Isolating those veins (“locking the naughty kids in”) helps most when patients are still early in the AF journey. Once the atrium is a “bush forest” of substrate, the same weed-picking becomes far less rewarding.
What AF does — and does not — kill with
A reassuring line for patients: AF itself does not usually kill. People die from the consequences and from the treatments we use poorly:
- Heart failure driven or worsened by uncontrolled rates or loss of atrial kick
- Thromboembolism / stroke (and bleeding from anticoagulation)
- Rare catastrophic conduction in accessory-pathway patients
- Proarrhythmia from antiarrhythmic drugs (“antiarrhythmics are also proarrhythmics”)
Day-to-day morbidity matters more than abstract mortality slides: breathlessness, reduced exercise tolerance, anxiety, CKD links, MI risk, and quality of life. Stroke risk assessment (CHA2DS2-VASc and local equivalents) is assumed GP knowledge here — the talk focused more on symptoms and rhythm strategy.
Catching AF: watches, Holters and loop recorders
Early AF is intermittent, so diagnosis is often a capture problem. Consumer tools help, with caveats:
- Smartwatches: useful screens, not perfect. Automated AF percentages rarely read “0%” even in people without clinical AF — treat alerts as prompts for proper ECG review.
- Apple Watch / Kardia-style single-lead ECGs: generally more useful than optical-only guesses; still need clinician verification.
- Holter / multi-day ambulatory monitors: common next step (e.g. 5–7 day monitoring from a cardiology centre).
- Implantable loop recorders: reserved when missing even brief AF matters — classic example cryptogenic stroke.
Risk-factor modification
Cardiologists can jump straight to “the procedure.” Dr Choo stressed partnership: ablation or cardioversion fails more often when triggers keep firing.
Weight
Higher BMI tracks with higher AF burden and worse symptoms. Meaningful weight loss can reduce AF burden and symptoms — sometimes as effectively as ablation for selected patients. A practical local threshold discussed among colleagues: aim for BMI under about 35 before elective AF ablation. BMI 25 as a hard cut-off would exclude almost everyone; BMI 40+ needs serious weight work first. Rules bend for progressive heart failure where AF must be treated urgently — but weight remains part of the plan, not optional garnish.
Alcohol
Alcohol is a clear AF provocateur. Abstinence (or near-abstinence) improves freedom from AF in studies. One “sweet spot” discussed was around one standard drink — not “fix my AF so I can keep drinking heavily.” Treatment is a partnership; the EP’s catheter cannot outrun ongoing heavy alcohol use.
Caffeine
Evidence does not support routine caffeine bans to prevent AF. American guidance cited in the talk: recommending caffeine abstention to prevent AF is of no benefit, though it may reduce symptoms in people who clearly notice a caffeine trigger. Practical answer: one or two cups is usually fine; ten cups is not a clinical strategy.
Rate vs rhythm control and cardioversion
Once AF is confirmed, choose a strategy:
- Rate control: accept AF; slow the ventricle (beta-blockers, non-dihydropyridine calcium-channel blockers) by increasing AV-node block.
- Rhythm control: try to restore and maintain sinus rhythm (drugs, cardioversion, ablation).
Younger patients, highly symptomatic patients, paroxysmal AF, heart failure with AF contribution, and clear patient preference for sinus rhythm.
DC cardioversion — reboot, not repair
Cardioversion is like turning a frozen computer off and on: it resets the rhythm; it does not fix the wiring. Success has two parts:
- Acute technical success is very high if enough energy is delivered (large patients may need creative pad setups).
- Staying in sinus depends on how advanced the AF journey is — days of paroxysmal AF versus ten years of persistent AF behave very differently.
ESC framing from the talk: cardioversion is reasonable for symptomatic patients; a wait-and-see approach for spontaneous conversion within 48 hours is also reasonable if the patient is not unwell. GPs and ED teams do not need to panic-cardiovert every new AF if the patient is stable — rate control, anticoagulation assessment, and timely specialist contact often suffice.
Some patients insist they feel fine after months or years in AF — then feel “five years younger” after a trial cardioversion. If you are unsure whether symptoms are present, a supervised trial of sinus rhythm can reveal a quality-of-life win you would otherwise miss.
Evidence snapshot: ablation vs drugs
Several trials discussed (including CABANA-era ablation vs drug therapy, EAST-AFNET-style early rhythm control, cryoballoon vs drugs, and even a controversial sham-ablation comparison) point the same way: catheter ablation reduces AF recurrence more than drug therapy alone in appropriately selected patients. Ablation is not magic immortality — it is better weed control while the garden is still manageable.
Catheter ablation: pulmonary vein isolation
Historic surgical maze procedures literally cut and rejoined atrium — highly effective substrate disruption, highly invasive. Surgical AF work today is usually adjunctive during valve or bypass surgery (quick clamp/linear lesions); pulmonary vein isolation is often incomplete, so EP redo work is common.
The cornerstone of modern AF ablation remains Professor Haïssaguerre’s 1998 insight: most AF triggers live in the pulmonary veins. Catheter ablation isolates those veins endocardially via femoral access, guided by fluoroscopy and 3D mapping (“GPS” patches like satellites so the catheter knows where it is).
AF ablation is journey care. Veins can reconnect; substrate can progress with age. A “failed” redo often finds that ~90% of prior lines still look good — a small gap is enough for AF to return. Reducing daily persistent AF to rare episodes is still a clinical win even if “complete cure” language is avoided.
Thermal vs pulsed field ablation
| Approach | Idea | Notes from the talk |
|---|---|---|
| Radiofrequency | Heat to create lines of scar | Point-by-point PVI; effective; thermal collateral risk (oesophagus, phrenic nerve) |
| Cryoballoon | Freeze (e.g. around −40 °C) | Historically popular; less favoured locally now vs newer energy |
| Pulsed field ablation (PFA) | Brief electrical fields preferentially injure myocardial cells | Described as safer for nearby nerves/oesophagus; Boston Scientific system in use ~3 years; can shrink a ~2.5 h case toward ~40 minutes |
Emerging platforms mentioned (for hospital purchasing conversations): Medtronic Affera-style systems and Abbott Volt — aiming for faster, safer PVI that fits existing mapping ecosystems.
AV node ablation + pacemaker — palliative rate control
When rhythm control is no longer realistic, ablating the AV node permanently blocks conduction to the ventricle. A pacemaker must go in first (otherwise there is no escape rhythm). Afterward, patients no longer need escalating beta-blockers, calcium-channel blockers, or amiodarone for rate — the ventricle is paced and “never races” again. It is irreversible pacemaker dependence: excellent symptom relief for the right patient, framed honestly as palliative rate control rather than cure of AF.
Timing, progression and guidelines
AF usually progresses: brief paroxysmal episodes → more frequent episodes → persistent AF → eventually “permanent” when everyone stops trying for sinus rhythm. Stroke/hospitalisation risk and atrial scarring climb along that path. Waiting ten years of continuous AF and then asking for a first ablation is often too late — the garden has become forest.
An Australian mentor study pattern (diagnosis-to-ablation time) was highlighted: ablation within about the first 12 months after diagnosis associates with better AF freedom than late ablation. The first 90 days after ablation are a blanking period while the atrium heals — early recurrences then do not automatically equal long-term failure.
A “first episode” referral may hide multiple ED visits over the next year. One illustrative case progressed to heavy scarring, two ablations in three months, then pacemaker + AV node ablation. Early review beats false reassurance from a single quiet clinic visit.
Guideline snapshot (as presented)
| Guideline | Ablation after failed/intolerant drugs (symptomatic) | Ablation as first-line rhythm strategy |
|---|---|---|
| ACC/AHA 2023 | Class 1 — improve symptoms | Useful as first-line in selected younger, fewer-comorbidity, symptomatic patients wanting rhythm control (also to slow progression) |
| ESC | Class 1 framing similar | Class 1 option within shared decision-making for first-line rhythm control |
| Australian 2023 (speaker on committee) | Supported | Class 2A — deliberately not “everyone first-line”; still a strong recommendation, resource-aware |
Practical translation for GPs: do not burn through years of antiarrhythmics before referring symptomatic patients who want rhythm control — especially while AF is still paroxysmal.
Specific scenarios GPs ask about
Triggered / perioperative AF
AF after infection or after surgery is common. Long-term anticoagulation still hinges mainly on stroke-risk score, not on the story that “it was only after the hernia repair.” Patients who fibrillate after minor surgery may have unrecognised intrinsic AF; high CHA2DS2-VASc usually means long-term anticoagulation unless contraindicated.
Stroke despite anticoagulation
About one third of patients with stroke are already on anticoagulants. Look for non-cardiac causes, carotid disease, dosing/adherence problems, and whether antiplatelet stacking is appropriate. Do not routinely add antiplatelets on top of anticoagulation without a clear indication; switching among anticoagulants may be considered when adherence or drug choice is the issue.
Stopping anticoagulation after “successful” ablation
Practice varies. Dr Choo’s personal approach: keep following the stroke-risk score. High-risk scores → continue anticoagulation even after years without documented AF, because ageing raises future AF likelihood and ablation is not promised as a cure. Low scores (e.g. 1–2) with documented freedom from AF → more room for shared decisions — still framed against guideline-based stroke prevention, not personal preference alone.
Paroxysmal vs persistent vs permanent
| Label | Working definition used in the talk |
|---|---|
| Paroxysmal | Terminates within 7 days (self or intervention) |
| Persistent | Continuous AF lasting longer — conventionally up toward a year before “long-standing” |
| Long-standing persistent | Continuous for >1 year, but sinus rhythm still actively pursued (ablation offered with lower success odds) |
| Permanent | Clinician and patient have stopped trying for sinus rhythm — a management decision, not a Holter label |
A 7-day Holter cannot define “permanent.” Check the last sinus ECG in the record: “five years of AF” is sometimes five years of intermittent awareness with a sinus tracing only months ago.
Subclinical AF on watches and implants
Monitor anyone long enough and you will find some AF. Truly asymptomatic patients without heart failure are not automatically ablation candidates — guidelines centre on symptom improvement and selected prognostic contexts, not “eradicate every smartphone blip.” Harder cases: athletes or professional pilots who are “asymptomatic” but cannot work with documented AF — shared decisions with clear discussion of procedural risk (order-of-magnitude figures cited: ~0.5% stroke/MI-type risk, ~1% tamponade/perforation), noting newer energy sources are making procedures safer.
Take-home messages for clinic
- AF needs a trigger and a substrate; early care targets triggers (often pulmonary veins), late care fights scarred atrium.
- Pair procedures with weight and alcohol work; caffeine bans are optional and symptom-driven.
- Stable new AF does not always need instant cardioversion — rate control, stroke-risk care, and a 48-hour window can be appropriate.
- Refer for rhythm strategy early while AF is still paroxysmal; Australian guidance supports ablation as a Class 2A first-line option in selected patients.
- After ablation, anticoagulation usually follows stroke risk, not the absence of recent AF alone; AV node ablation + pacing remains a powerful palliative rate tool.
Dr Kotha · Gold Coast · atrial-fibrillation.drkotha.com